Regulatory Submissions

Pre-market submissions define your timeline to market. EMMA International’s regulatory experts prepare comprehensive pharmaceutical, biologics, and medical device submissions. Whether combined with regulatory strategy or used as a standalone service, with EMMA International, you’re assured accurate, timely submissions that streamline your path to approval or clearance.

Pharmaceuticals

Pre-Investigational New Drug Application (Pre-IND)

Don’t forget the most important step on your path to market. EMMA International helps you navigate FDA requirements and prepare your pre-IND package, thus ensuring you gain valuable feedback from the FDA.

Investigational New Drug Application (IND)

EMMA International takes care of the heavy lifting to prepare a comprehensive IND package so you can start your clinical investigation.

Abbreviated New Drug Application/New Drug Application (ANDA/NDA)

Our regulatory experts compile your abbreviated new drug application or new drug application to ensure your drug product reaches all the commercialization milestones on your timeline.

Biologics

Pre- Investigational New Drug /Pre- Investigational Device Exemption

Don’t forget the most important step on your path to market. EMMA International helps you navigate FDA requirements and prepare your pre-IND package, thus ensuring you gain valuable feedback from the FDA.

Investigational New Drug (IND) or Investigational Device Exemption (IDE)

EMMA International prepares your investigational submission package to assure your readiness for clinical investigation.

Biologics License Application (BLA)

Our regulatory experts work alongside your stakeholders to compile your BLA. Our track record of successful approvals speaks for itself.

Medical Devices/Digital Health

Pre- Investigational Device Exemption

Don’t forget the most important step on your path to market. EMMA International helps you navigate FDA requirements and prepare your pre-IDE package, as applicable, thus ensuring you gain valuable feedback from the FDA.

Investigational Device Exemption (IDE)

EMMA International can prepare your investigational submission package to ensure your readiness for clinical investigation.

Q-Submissions

Getting innovative products to market can be a daunting task. With EMMA International on your side, a Q-Sub becomes an even more valuable mechanism to obtain some feedback from the FDA. We compile the documentation, facilitate pre-submissions and meetings with the FDA, and address all concerns raised by the agency on your behalf.

510(k)/ Premarket Approval (PMA)/ DeNovo/Humanitarian Device Exemption (HDE)

From former FDA officials to former regulatory affairs executives, our regulatory experts guarantee the outcome of your regulatory submissions regardless of complexity.

Ready to get expert assistance with your regulatory submissions? Speak with one of our experts today.

Ready to learn more about working with us?

Regulatory Submission Resources

Applying ISO 14971 to AI/ML

Applying ISO 14971 to AI/ML

Everyone is aware that ISO 14971 is the gold standard for risk management of medical devices. As the regulatory landscape evolves to forge a path for innovative technology like AI/ML devices, it begs the question of how to apply our existing systems and methodologies to novel technology that is inevitably the future of healthcare.
Understanding Biosimilar Products

Understanding Biosimilar Products

A Biosimilar is essentially a biologic product that is similar and has no clinically significant difference in terms of safety, purity, and potency from an existing approved Biologic on the market.
The FDA and AI/ML in Medical Devices: Navigating the Future of Healthcare

The FDA and AI/ML in Medical Devices: Navigating the Future of Healthcare

Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing healthcare, offering unprecedented opportunities to improve patient outcomes, streamline processes, and enhance diagnostic accuracy. As AI and ML continue to make significant strides in the medical field, the U.S. Food and Drug Administration (FDA) plays a pivotal role in regulating these innovations. In this blog post, we'll explore the intersection of AI/ML and medical devices, and how the FDA is navigating this rapidly evolving landscape.
The FDA’s Update to Biocompatibility Guidance

The FDA’s Update to Biocompatibility Guidance

The FDA’s guidance document on the use of ISO 10993-1 was updated this month with some crucial information for medical device manufacturers. Biocompatibility testing has been a long-standing requirement for a majority of device manufacturers, so this update that includes some excluded materials and devices is a welcome change.

Pin It on Pinterest